Published in Blood Cells Mol Dis on August 06, 2007
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 1.52
Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood (2008) 1.09
Toll-like receptors mediate induction of hepcidin in mice infected with Borrelia burgdorferi. Blood (2009) 0.96
Sustained submicromolar H2O2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3). J Biol Chem (2012) 0.88
Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice. Cytokine (2011) 0.88
A multi-scale model of hepcidin promoter regulation reveals factors controlling systemic iron homeostasis. PLoS Comput Biol (2014) 0.79
Ceramide Induces Human Hepcidin Gene Transcription through JAK/STAT3 Pathway. PLoS One (2016) 0.75
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest (2002) 7.90
A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab (2005) 4.79
Interleukin-6 induces hepcidin expression through STAT3. Blood (2006) 4.24
Regulation of iron metabolism by hepcidin. Annu Rev Nutr (2006) 3.96
STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood (2006) 3.38
Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A (2006) 3.13
Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A (2005) 3.11
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell (2007) 2.99
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Identification of a novel TGF-beta-regulated gene encoding a putative zinc finger protein in human osteoblasts. Nucleic Acids Res (1995) 1.89
TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene (2002) 1.53
Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J Biol Chem (2000) 1.48
Functional differences between hepcidin 1 and 2 in transgenic mice. Blood (2003) 1.45
Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol (2007) 1.33
Cis and trans regulation of hepcidin expression by upstream stimulatory factor. Blood (2006) 1.22
Transcriptional regulation of Smad2 is required for enhancement of TGFbeta/Smad signaling by TGFbeta inducible early gene. J Cell Biochem (2002) 1.22
Different expression pattern of hepcidin genes in the liver and pancreas of C57BL/6N and DBA/2N mice. J Hepatol (2004) 1.01
The serine protease TMPRSS6 is required to sense iron deficiency. Science (2008) 3.70
The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis (2009) 3.44
Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A (2006) 3.13
Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A (2005) 3.11
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency. Br J Haematol (2010) 2.20
The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A (2004) 2.18
Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood (2007) 1.75
A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A (2002) 1.74
Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc (2002) 1.71
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension (2006) 1.64
Haptoglobin polymorphism and iron homeostasis. Clin Chem (2002) 1.63
Regulation of hepcidin and iron-overload disease. Annu Rev Pathol (2009) 1.58
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood (2006) 1.47
Natural history of hemochromatosis. Mayo Clin Proc (2004) 1.43
Penetrance of hemochromatosis. Blood Cells Mol Dis (2003) 1.43
Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6. Br J Haematol (2009) 1.36
Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol (2007) 1.33
Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis (2005) 1.30
Pro-active call center treatment support (PACCTS) to improve glucose control in type 2 diabetes: a randomized controlled trial. Diabetes Care (2005) 1.20
Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood (2004) 1.20
Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol (2005) 1.20
The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol (2005) 1.16
A new case of human atransferrinemia with a previously undescribed mutation in the transferrin gene. Acta Haematol (2007) 1.16
Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood (2008) 1.09
Effect of correcting transferrin saturation for body mass index in HFE C282Y homozygotes. J Hepatol (2005) 1.08
In vivo imaging of hepcidin promoter stimulation by iron and inflammation. Blood Cells Mol Dis (2007) 1.07
Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis (2003) 1.06
The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet (2006) 1.05
Haemoglobin and ferritin concentrations in men and women: cross sectional study. BMJ (2002) 1.04
Structure and function correlation in histone H2A peptide-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.04
Identification of a novel mutation in the CDHR1 gene in a family with recessive retinal degeneration. Arch Ophthalmol (2012) 1.02
The distal location of the iron responsive region of the hepcidin promoter. Blood (2007) 1.02
Brain iron metabolism and neurodegenerative disorders. Dev Neurosci (2002) 0.98
Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol (2011) 0.95
Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis (2003) 0.94
Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity. Blood Cells Mol Dis (2007) 0.93
Exome analysis identified a novel mutation in the RBP4 gene in a consanguineous pedigree with retinal dystrophy and developmental abnormalities. PLoS One (2012) 0.93
Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med (2002) 0.93
Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol (2004) 0.92
The anemia of ageing is not associated with increased plasma hepcidin levels. Blood Cells Mol Dis (2008) 0.90
Genetic screening for low-penetrance variants in protein-coding genes. Annu Rev Genomics Hum Genet (2009) 0.89
Carrier screening for Gaucher disease: more harm than good? JAMA (2007) 0.89
Three kinships with ALAS2 P520L (c. 1559 C --> T) mutation, two in association with severe iron overload, and one with sideroblastic anemia and severe iron overload. Blood Cells Mol Dis (2006) 0.88
Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin Exp Res (2007) 0.87
Erythrocyte viability in blood salvaged during total joint arthroplasty with cement. J Bone Joint Surg Am (2002) 0.86
Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase deficiency. Blood (2002) 0.86
Soluble transferrin receptor-1 levels in mice do not affect iron absorption. Acta Haematol (2006) 0.85
Tumor necrosis factor alpha promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A(C282Y) hereditary hemochromatosis mutation. Blood (2002) 0.84
Asian genotypes of JC virus in Japanese-Americans suggest familial transmission. J Virol (2002) 0.84
Gene therapy of human disease. Medicine (Baltimore) (2002) 0.84
Iron overload secondary to cirrhosis: a mimic of hereditary haemochromatosis? Histopathology (2014) 0.83
Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol (2004) 0.83
The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol (2006) 0.82
Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. Blood Cells Mol Dis (2002) 0.82
Severe iron overload with a novel aminolevulinate synthase mutation and hepatitis C infection. A case report. Blood Cells Mol Dis (2008) 0.82
Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis (2005) 0.82
Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol (2006) 0.82
Beware of multiple comparisons: a study of symptoms associated with mutations of the HFE hemochromatosis gene. Clin Chim Acta (2005) 0.81
Mixture distribution analysis of phenotypic markers reflecting HFE gene mutations. Blood (2003) 0.81
Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med (2008) 0.81
The C282Y mutation does not shorten life span. Arch Intern Med (2002) 0.80
Congenital Gaucher disease with nonimmune hydrops/erythroblastosis, infantile arterial calcification, and neonatal hepatitis/fibrosis. Clinicopathologic report with enzymatic and genetic analysis. Fetal Pediatr Pathol (2007) 0.80
Cladribine in the treatment of hairy-cell leukaemia. Best Pract Res Clin Haematol (2003) 0.79
A juvenile hemochromatosis patient homozygous for a novel deletion of cDNA nucleotide 81 of hemojuvelin. Acta Haematol (2006) 0.79
Iron absorption in carriers of the C282Y hemochromatosis mutation. Am J Clin Nutr (2004) 0.78
Response to Moirand et al.-"HFE based re-evaluation of heterozygous hemochromatosis". Am J Med Genet A (2004) 0.77
The genetic basis of human erythrocyte pyridoxal kinase activity variation. Haematologica (2006) 0.77
The clinical penetrance of hereditary hemochromatosis. Hepatology (2003) 0.77
Characteristics of HFE C282Y homozygotes younger than age 30 years. Acta Haematol (2004) 0.77
The 1604A (R496H) mutation in Gaucher disease: genotype/phenotype correlation. Blood Cells Mol Dis (2003) 0.77
Polymorphisms in the human homologue of the drosophila Indy (I'm not dead yet) gene. Mech Ageing Dev (2003) 0.77
Molecular characterization of a third case of human atransferrinemia. Blood (2004) 0.77
Glucose-6-phosphate dehydrogenase (G6PD) deficiency-type Zurich: a splice site mutation as an uncommon mechanism producing enzyme deficiency. Blood (2004) 0.77
Hematologically important mutations: iron storage diseases. Blood Cells Mol Dis (2004) 0.76
Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med (2008) 0.75
Metastatic carcinomatous cirrhosis and hepatic hemosiderosis. Arch Pathol Lab Med (2002) 0.75
Response to the letter by Nicolas et al, BJH-2010-01422. Br J Haematol (2011) 0.75
Case 20-2003: Gaucher's disease. N Engl J Med (2004) 0.75
Consensus recommendations. Br J Haematol (2007) 0.75
A late presentation of a fatal disease: juvenile hemochromatosis. Case Rep Med (2013) 0.75
Hereditary hemochromatosis: screening and management. Curr Hematol Rep (2006) 0.75
Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease. Mov Disord (2002) 0.75
No age-related decrease in frequency of heterozygotes for the HFE C282Y haemochromatosis mutation. J Hepatol (2004) 0.75
Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med (2002) 0.75
The effect of HFE genotypes on measurements of iron overload. Ann Intern Med (2002) 0.75
Screening strategies in C282Y-linked haemochromatosis. Br J Haematol (2003) 0.75